Matching articles for "amlodipine"

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • May 27, 2024;  (Issue 1703)
American College of Cardiology/American Heart Association (ACC/AHA) guidelines for treatment of hypertension were last published in 2018. Treatment of hypertensive urgencies and emergencies is not discussed...
American College of Cardiology/American Heart Association (ACC/AHA) guidelines for treatment of hypertension were last published in 2018. Treatment of hypertensive urgencies and emergencies is not discussed here.
Med Lett Drugs Ther. 2024 May 27;66(1703):81-8 | Show Full IntroductionHide Full Introduction

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • May 18, 2020;  (Issue 1598)
Drugs available for treatment of chronic hypertension and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed...
Drugs available for treatment of chronic hypertension and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.
Med Lett Drugs Ther. 2020 May 18;62(1598):73-80 | Show Full IntroductionHide Full Introduction

Consensi - A Fixed-Dose Combination of Amlodipine and Celecoxib

   
The Medical Letter on Drugs and Therapeutics • March 9, 2020;  (Issue 1593)
Consensi (Coeptis/Burke), a fixed-dose combination of the calcium channel blocker amlodipine (Norvasc, and others) and the COX-2 selective NSAID celecoxib (Celebrex, and generics), has been approved by the...
Consensi (Coeptis/Burke), a fixed-dose combination of the calcium channel blocker amlodipine (Norvasc, and others) and the COX-2 selective NSAID celecoxib (Celebrex, and generics), has been approved by the FDA for treatment of patients who have hypertension and osteoarthritis.
Med Lett Drugs Ther. 2020 Mar 9;62(1593):39-40 | Show Full IntroductionHide Full Introduction

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • March 13, 2017;  (Issue 1516)
in the US and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed...
in the US and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.
Med Lett Drugs Ther. 2017 Mar 13;59(1516):41-8 | Show Full IntroductionHide Full Introduction

Byvalson - A Beta Blocker/ARB Combination for Hypertension

   
The Medical Letter on Drugs and Therapeutics • September 12, 2016;  (Issue 1503)
The FDA has approved Byvalson (Allergan), a fixed-dose combination of the beta blocker nebivolol (Bystolic) and the angiotensin receptor blocker (ARB) valsartan (Diovan, and generics), for treatment...
The FDA has approved Byvalson (Allergan), a fixed-dose combination of the beta blocker nebivolol (Bystolic) and the angiotensin receptor blocker (ARB) valsartan (Diovan, and generics), for treatment of hypertension. It is the only combination product that contains nebivolol, and the first to combine a beta blocker with an ARB.
Med Lett Drugs Ther. 2016 Sep 12;58(1503):115-7 | Show Full IntroductionHide Full Introduction

Prestalia - Another Combination for Hypertension

   
The Medical Letter on Drugs and Therapeutics • July 20, 2015;  (Issue 1473)
The FDA has approved Prestalia (Symplmed), an oral fixed-dose combination of the dihydropyridine calcium channel blocker amlodipine (Norvasc, and generics) and a new salt form of the...
The FDA has approved Prestalia (Symplmed), an oral fixed-dose combination of the dihydropyridine calcium channel blocker amlodipine (Norvasc, and generics) and a new salt form of the angiotensin-converting enzyme (ACE) inhibitor perindopril, for treatment of hypertension in patients not adequately controlled on monotherapy or already taking both drugs, and in those just starting therapy who are likely to need multiple drugs to control their blood pressure. The new salt form (perindopril arginine) is more stable and has a longer shelf-life than perindopril erbumine (Aceon, and generics). Two other ACE inhibitor/calcium channel blocker combinations, benazepril/amlodipine (Lotrel, and generics) and trandolapril/verapamil ER (Tarka, and generics), have been available in the US for many years.
Med Lett Drugs Ther. 2015 Jul 20;57(1473):103-4 | Show Full IntroductionHide Full Introduction

A 4-Drug Combination (Viekira Pak) for Hepatitis C

   
The Medical Letter on Drugs and Therapeutics • February 2, 2015;  (Issue 1461)
The FDA has approved Viekira Pak (Abbvie), a fixed-dose combination of two new direct-acting antiviral agents (ombitasvir, paritaprevir) with the pharmacologic enhancer ritonavir in one tablet, co-packaged...
The FDA has approved Viekira Pak (Abbvie), a fixed-dose combination of two new direct-acting antiviral agents (ombitasvir, paritaprevir) with the pharmacologic enhancer ritonavir in one tablet, co-packaged with a third new direct-acting antiviral agent (dasabuvir) in a second tablet, for oral treatment of chronic hepatitis C virus (HCV) genotype 1 infection. Genotype 1 is responsible for 70-80% of HCV infections in the US.
Med Lett Drugs Ther. 2015 Feb 2;57(1461):15-7 | Show Full IntroductionHide Full Introduction

Treatment of Atrial Fibrillation

   
The Medical Letter on Drugs and Therapeutics • July 7, 2014;  (Issue 1446)
The treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. New US guidelines for the management of atrial fibrillation have recently been...
The treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. New US guidelines for the management of atrial fibrillation have recently been published.
Med Lett Drugs Ther. 2014 Jul 7;56(1446):53-8 | Show Full IntroductionHide Full Introduction

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • January 1, 2012;  (Issue 113)
Drugs available in the US for treatment of chronic hypertension, with their dosages and adverse effects, are listed in the tables that begin on page 2. Combination products are listed on page 8. Drugs...
Drugs available in the US for treatment of chronic hypertension, with their dosages and adverse effects, are listed in the tables that begin on page 2. Combination products are listed on page 8. Drugs for treatment of hypertensive emergencies are not discussed here. They were reviewed previously.
Treat Guidel Med Lett. 2012 Jan;10(113):1-10 | Show Full IntroductionHide Full Introduction

New Simvastatin Dosing Recommendations

   
The Medical Letter on Drugs and Therapeutics • August 8, 2011;  (Issue 1370)
The FDA has announced changes in the labeling of simvastatin to reduce the risk of myopathy. These changes include limiting the use of the 80-mg maximum dose to patients who have been taking it for 12 months or...
The FDA has announced changes in the labeling of simvastatin to reduce the risk of myopathy. These changes include limiting the use of the 80-mg maximum dose to patients who have been taking it for 12 months or more without evidence of myopathy and new recommendations for use of simvastatin with other drugs. Simvastatin is available alone (Zocor, and others) and in combination with ezetimibe (Vytorin) and with niacin (Simcor).
Med Lett Drugs Ther. 2011 Aug 8;53(1370):61-2 | Show Full IntroductionHide Full Introduction

In Brief: Another Three-Drug Combination for Hypertension

   
The Medical Letter on Drugs and Therapeutics • April 4, 2011;  (Issue 1361)
The FDA has approved aliskiren/amlodipine/hydrochlorothiazide (Amturnide) for treatment of hypertension, with no restrictions except that it should not be used for initial therapy. A combination of the direct...
The FDA has approved aliskiren/amlodipine/hydrochlorothiazide (Amturnide) for treatment of hypertension, with no restrictions except that it should not be used for initial therapy. A combination of the direct renin inhibitor aliskiren and the calcium channel blocker amlodipine (Tekamlo) was approved earlier for initial treatment.1

Use of combination tablets is, of course, more convenient than taking the components separately, and as long as all the same doses are available and the cost is no greater, there is no reason not to use them.

Aliskiren alone or in combination has not been shown to improve clinical outcomes.2 Whether it offers any advantage over the angiotensin receptor blockers (ARBs), which are also available in various antihypertensive combinations, remains to be determined.

1. Aliskiren/amlodipine (Tekamlo): another combination tablet for hypertension. Med Lett Drugs Ther 2010; 52:94.

2. Drugs for hypertension. Treat Guidel Med Lett 2009; 7:1.

Download U.S. English
Med Lett Drugs Ther. 2011 Apr 4;53(1361):28 | Show Full IntroductionHide Full Introduction

Aliskiren/Amlodipine (Tekamlo): Another Combination Tablet for Hypertension

   
The Medical Letter on Drugs and Therapeutics • November 29, 2010;  (Issue 1352)
The FDA has approved Tekamlo (Novartis), an oral fixed-dose combination of the direct renin inhibitor aliskiren (Tekturna) and the calcium channel blocker amlodipine (Norvasc, and others), for treatment...
The FDA has approved Tekamlo (Novartis), an oral fixed-dose combination of the direct renin inhibitor aliskiren (Tekturna) and the calcium channel blocker amlodipine (Norvasc, and others), for treatment of hypertension in patients not adequately controlled on monotherapy or already taking both drugs, and as initial therapy in those likely to need multiple drugs to control their blood pressure (BP). Both aliskiren and amlodipine are available in combinations with other antihypertensive agents.
Med Lett Drugs Ther. 2010 Nov 29;52(1352):94-5 | Show Full IntroductionHide Full Introduction

Tribenzor for Hypertension

   
The Medical Letter on Drugs and Therapeutics • September 6, 2010;  (Issue 1346)
Many patients with hypertension require more than one drug to control their blood pressure. Tribenzor (Daiichi Sankyo), recently approved by the FDA for treatment of hypertension, combines the calcium channel...
Many patients with hypertension require more than one drug to control their blood pressure. Tribenzor (Daiichi Sankyo), recently approved by the FDA for treatment of hypertension, combines the calcium channel blocker amlodipine (Norvasc, and others), the angiotensin receptor blocker (ARB) olmesartan (Benicar)and the most commonly prescribed diuretic, hydrochlorothiazide (HCTZ). Tribenzor is not approved for initial therapy, but is recommended for patients not adequately controlled on any 2-drug combination of a calcium channel blocker, an ARB or a diuretic.
Med Lett Drugs Ther. 2010 Sep 6;52(1346):70-1 | Show Full IntroductionHide Full Introduction

A Third Amlodipine/ARB Combination (Twynsta) for Hypertension

   
The Medical Letter on Drugs and Therapeutics • January 11, 2010;  (Issue 1329)
The FDA has approved Twynsta (Boehringer Ingelheim), a fixed-dose combination of the calcium-channel blocker (CCB) amlodipine and the angiotensin receptor blocker (ARB) telmisartan, for treatment of...
The FDA has approved Twynsta (Boehringer Ingelheim), a fixed-dose combination of the calcium-channel blocker (CCB) amlodipine and the angiotensin receptor blocker (ARB) telmisartan, for treatment of hypertension.
Med Lett Drugs Ther. 2010 Jan 11;52(1329):2-3 | Show Full IntroductionHide Full Introduction

Tablet Splitting

   
The Medical Letter on Drugs and Therapeutics • August 10, 2009;  (Issue 1318)
Readers have asked us to update our 2004 article on tablet splitting. Breaking drug tablets in half is a common practice, but the FDA recently advised consumers against it (FDA Consumer Health Information, July...
Readers have asked us to update our 2004 article on tablet splitting. Breaking drug tablets in half is a common practice, but the FDA recently advised consumers against it (FDA Consumer Health Information, July 2009).

Med Lett Drugs Ther. 2009 Aug 10;51(1318):62-3 | Show Full IntroductionHide Full Introduction

Exforge HCT

   
The Medical Letter on Drugs and Therapeutics • June 15, 2009;  (Issue 1314)
Most patients with hypertension require more than one drug to control their blood pressure. Exforge HCT (Novartis) is a new 3-drug fixed-dose combination tablet approved by the FDA for treatment of...
Most patients with hypertension require more than one drug to control their blood pressure. Exforge HCT (Novartis) is a new 3-drug fixed-dose combination tablet approved by the FDA for treatment of hypertension. It combines the calcium-channel blocker amlodipine (Norvasc, and others) and the angiotensin receptor blocker (ARB) valsartan (Diovan), which are already available in a combination tablet (Exforge), with the most commonly prescribed diuretic hydrochlorothiazide (HCTZ). Exforge HCT is not approved for initial treatment of hypertension, but rather for patients not adequately controlled on a 2-drug combination of a calcium-channel blocker, an ARB or a diuretic. It can also be substituted for amlodipine, valsartan and HCTZ in patients already taking all 3 of these drugs.
Med Lett Drugs Ther. 2009 Jun 15;51(1314):46 | Show Full IntroductionHide Full Introduction

A Diuretic for Initial Treatment of Hypertension?

   
The Medical Letter on Drugs and Therapeutics • February 9, 2009;  (Issue 1305)
Effective treatment of hypertension can prevent organ damage and death. The choice of drugs for initial treatment continues to be...
Effective treatment of hypertension can prevent organ damage and death. The choice of drugs for initial treatment continues to be controversial.
Med Lett Drugs Ther. 2009 Feb 9;51(1305):9-10 | Show Full IntroductionHide Full Introduction

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • January 1, 2009;  (Issue 77)
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 2. Combination products are listed on page 9. Drugs...
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 2. Combination products are listed on page 9. Drugs for treatment of hypertensive emergencies are not discussed here. They were reviewed in Treatment Guidelines (volume 1, page 19, December 2002) and in The Medical Letter (volume 50, page 73, September 22, 2008).
Treat Guidel Med Lett. 2009 Jan;7(77):1-10 | Show Full IntroductionHide Full Introduction

Nebivolol (Bystolic) for Hypertension

   
The Medical Letter on Drugs and Therapeutics • March 10, 2008;  (Issue 1281)
Nebivolol (Bystolic - Forest) is a new beta-blocker that has been approved by the FDA for treatment of hypertension. It has been marketed in Europe since 1999 for treatment of hypertension and heart...
Nebivolol (Bystolic - Forest) is a new beta-blocker that has been approved by the FDA for treatment of hypertension. It has been marketed in Europe since 1999 for treatment of hypertension and heart failure.
Med Lett Drugs Ther. 2008 Mar 10;50(1281):17-9 | Show Full IntroductionHide Full Introduction

Two Amlodipine/ARB Combinations for Hypertension

   
The Medical Letter on Drugs and Therapeutics • December 17, 2007;  (Issue 1276)
The FDA has approved Exforge (Novartis) and Azor (Daiichi Sankyo), the first combinations of a calcium channel blocker (CCB) with an angiotensin receptor blocker (ARB) for treatment of hypertension. Amlodipine...
The FDA has approved Exforge (Novartis) and Azor (Daiichi Sankyo), the first combinations of a calcium channel blocker (CCB) with an angiotensin receptor blocker (ARB) for treatment of hypertension. Amlodipine is the CCB in both products. The ARBs are valsartan in Exforge and olmesartan in Azor. All 3 of these drugs are available in fixed-dose combinations with other antihypertensive drugs.
Med Lett Drugs Ther. 2007 Dec 17;49(1276):101-2 | Show Full IntroductionHide Full Introduction

Sildenafil (Revatio) for Pulmonary Arterial Hypertension

   
The Medical Letter on Drugs and Therapeutics • August 15, 2005;  (Issue 1215)
The Medical Letter reported last year that sildenafil (Viagra - Pfizer) appeared to be effective for idiopathic pulmonary arterial hypertension (PAH), but confirmation from a controlled trial was needed. Now...
The Medical Letter reported last year that sildenafil (Viagra - Pfizer) appeared to be effective for idiopathic pulmonary arterial hypertension (PAH), but confirmation from a controlled trial was needed. Now the results of such a study are about to be published, and the drug has been approved by the FDA for this indication under the trade name Revatio.
Med Lett Drugs Ther. 2005 Aug 15;47(1215):65-7 | Show Full IntroductionHide Full Introduction

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • June 1, 2005;  (Issue 34)
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 40. Combination products are listed on page 47. Drugs...
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 40. Combination products are listed on page 47. Drugs for treatment of hypertensive emergencies are not discussed here.
Treat Guidel Med Lett. 2005 Jun;3(34):39-48 | Show Full IntroductionHide Full Introduction

ARBs and Myocardial Infarction

   
The Medical Letter on Drugs and Therapeutics • May 9, 2005;  (Issue 1208)
Angiotensin receptor blockers (ARBs) are widely used as an alternative to angiotensin converting enzyme (ACE) inhibitors for treatment of hypertension because they lower blood pressure without inducing a cough....
Angiotensin receptor blockers (ARBs) are widely used as an alternative to angiotensin converting enzyme (ACE) inhibitors for treatment of hypertension because they lower blood pressure without inducing a cough. It has not been established that they provide the same cardiac benefits as ACE inhibitors. Recently, an editorial in the British Medical Journal suggested that ARBs may increase the risk of myocardial infarction.
Med Lett Drugs Ther. 2005 May 9;47(1208):38-9 | Show Full IntroductionHide Full Introduction

Tablet Splitting

   
The Medical Letter on Drugs and Therapeutics • November 8, 2004;  (Issue 1195)
Breaking drug tablets in half is a common practice. In some cases, a lower drug dose may be as effective as a higher one, with fewer adverse effects. Sometimes tablets are split to achieve an intermediate dose...
Breaking drug tablets in half is a common practice. In some cases, a lower drug dose may be as effective as a higher one, with fewer adverse effects. Sometimes tablets are split to achieve an intermediate dose between marketed strengths. When 2 tablet sizes cost the same, as they often do, splitting the larger size saves money. Is this a reasonable practice?
Med Lett Drugs Ther. 2004 Nov 8;46(1195):89-91 | Show Full IntroductionHide Full Introduction

Initial Therapy of Hypertension

   
The Medical Letter on Drugs and Therapeutics • July 5, 2004;  (Issue 1186)
The importance of adequate control of hypertension in preventing organ damage and death is well established, but the choice of drugs is still controversial. Three recent drug trials, one supporting initial...
The importance of adequate control of hypertension in preventing organ damage and death is well established, but the choice of drugs is still controversial. Three recent drug trials, one supporting initial therapy with a diuretic, the second favoring an angiotensin converting enzyme (ACE) inhibitor, and the third showing equivalence between a calcium-channel blocker and an angiotensin-receptor blocker (ARB) have intensified the debate.
Med Lett Drugs Ther. 2004 Jul 5;46(1186):53-5 | Show Full IntroductionHide Full Introduction

Amlodipine/Atorvastatin (Caduet)

   
The Medical Letter on Drugs and Therapeutics • July 5, 2004;  (Issue 1186)
Caduet (Pfizer), a combination of the calcium-channel blocker amlodipine (Norvasc - Pfizer) and the HMG-CoA reductase inhibitor (statin) atorvastatin (Lipitor - Pfizer), is now available in the US. It was...
Caduet (Pfizer), a combination of the calcium-channel blocker amlodipine (Norvasc - Pfizer) and the HMG-CoA reductase inhibitor (statin) atorvastatin (Lipitor - Pfizer), is now available in the US. It was approved by the FDA for use in patients with indications for treatment with both amlodipine, which is used to treat hypertension and/or angina pectoris, and atorvastatin, which is used to treat dyslipidemia. The combination is bioequivalent to the 2 components taken separately.
Med Lett Drugs Ther. 2004 Jul 5;46(1186):56 | Show Full IntroductionHide Full Introduction

Sildenafil for Pulmonary Hypertension

   
The Medical Letter on Drugs and Therapeutics • March 1, 2004;  (Issue 1177)
Several recent case reports suggest that oral sildenafil may be effective for treatment of pulmonary arterial hypertension (PAH). Sildenafil is currently marketed as Viagra for treatment of erectile dysfunction...
Several recent case reports suggest that oral sildenafil may be effective for treatment of pulmonary arterial hypertension (PAH). Sildenafil is currently marketed as Viagra for treatment of erectile dysfunction (Medical Letter 1998; 40:51).
Med Lett Drugs Ther. 2004 Mar 1;46(1177):18-9 | Show Full IntroductionHide Full Introduction

Eplerenone (Inspra)

   
The Medical Letter on Drugs and Therapeutics • May 12, 2003;  (Issue 1156)
Eplerenone (e pler' en one; Inspra - Pharmacia), an aldosterone receptor antagonist similar to spironolactone (Aldactone, and others), has been approved by the FDA, but not yet marketed, for treatment of...
Eplerenone (e pler' en one; Inspra - Pharmacia), an aldosterone receptor antagonist similar to spironolactone (Aldactone, and others), has been approved by the FDA, but not yet marketed, for treatment of hypertension. It has also been tried for treatment of heart failure.
Med Lett Drugs Ther. 2003 May 12;45(1156):39-40 | Show Full IntroductionHide Full Introduction

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • February 1, 2003;  (Issue 6)
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the table that begins on page 35. Combination products are listed on page 39. Drugs...
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the table that begins on page 35. Combination products are listed on page 39. Drugs for treatment of hypertensive emergencies were discussed in Treatment Guidelines volume 1, issue 4, page 19, December 2002.
Treat Guidel Med Lett. 2003 Feb;1(6):33-40 | Show Full IntroductionHide Full Introduction

Treprostinil (Remodulin) for Pulmonary Arterial Hypertension

   
The Medical Letter on Drugs and Therapeutics • September 16, 2002;  (Issue 1139)
Treprostinil sodium (tre prost' in il; Remodulin - United Therapeutics), a prostacyclin analogue, has been approved by the FDA for continuous subcutaneous (SC) treatment of patients with pulmonary arterial...
Treprostinil sodium (tre prost' in il; Remodulin - United Therapeutics), a prostacyclin analogue, has been approved by the FDA for continuous subcutaneous (SC) treatment of patients with pulmonary arterial hypertension who have dyspnea on more than minimal exertion (NYHA Class II-IV).
Med Lett Drugs Ther. 2002 Sep 16;44(1139):80-2 | Show Full IntroductionHide Full Introduction

Olmesartan (Benicar) for hypertension

   
The Medical Letter on Drugs and Therapeutics • August 5, 2002;  (Issue 1136)
Olmesartan medoxomil (Benicar - Sankyo), a substituted imidazole, is the seventh oral angiotensin II receptor blocker (ARB) approved by the FDA for treatment of...
Olmesartan medoxomil (Benicar - Sankyo), a substituted imidazole, is the seventh oral angiotensin II receptor blocker (ARB) approved by the FDA for treatment of hypertension.
Med Lett Drugs Ther. 2002 Aug 5;44(1136):69-70 | Show Full IntroductionHide Full Introduction

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • March 5, 2001;  (Issue 1099)
Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the...
Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the text.
Med Lett Drugs Ther. 2001 Mar 5;43(1099):17-22 | Show Full IntroductionHide Full Introduction

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • March 12, 1999;  (Issue 1048)
Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the...
Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the text.
Med Lett Drugs Ther. 1999 Mar 12;41(1048):23-8 | Show Full IntroductionHide Full Introduction

Candesartan for Hypertension

   
The Medical Letter on Drugs and Therapeutics • November 20, 1998;  (Issue 1040)
Candesartan cilexetil (Atacand - Astra) is the fourth angiotensin II receptor antagonist to become available in the USA for oral treatment of...
Candesartan cilexetil (Atacand - Astra) is the fourth angiotensin II receptor antagonist to become available in the USA for oral treatment of hypertension.
Med Lett Drugs Ther. 1998 Nov 20;40(1040):109-10 | Show Full IntroductionHide Full Introduction

Mibefradil--A New Calcium-Channel Blocker

   
The Medical Letter on Drugs and Therapeutics • November 7, 1997;  (Issue 1013)
Mibefradil dihydrochloride (Posicor - Roche), a chemically distinct nondihydropyridine calcium-channel blocker, has been approved by the US Food and Drug Administration (FDA) and is being heavily promoted as...
Mibefradil dihydrochloride (Posicor - Roche), a chemically distinct nondihydropyridine calcium-channel blocker, has been approved by the US Food and Drug Administration (FDA) and is being heavily promoted as the first T-type calcium-channel blocker for treatment of hypertension and chronic stable angina.
Med Lett Drugs Ther. 1997 Nov 7;39(1013):103-5 | Show Full IntroductionHide Full Introduction

Valsartan for Hypertension

   
The Medical Letter on Drugs and Therapeutics • April 25, 1997;  (Issue 999)
Valsartan (Diovan - Novartis), a non-peptide tetrazole, is the second angiotensin II receptor antagonist approved for oral treatment of hypertension by the US Food and Drug Administration. The first was...
Valsartan (Diovan - Novartis), a non-peptide tetrazole, is the second angiotensin II receptor antagonist approved for oral treatment of hypertension by the US Food and Drug Administration. The first was losartan (Cozaar - Medical Letter, 37:57, 1995).
Med Lett Drugs Ther. 1997 Apr 25;39(999):43-4 | Show Full IntroductionHide Full Introduction

Safety of Calcium-Channel Blockers

   
The Medical Letter on Drugs and Therapeutics • February 14, 1997;  (Issue 994)
Reports of increased mortality associated with calcium-channel blockers have caused concerns among patients taking these drugs and their...
Reports of increased mortality associated with calcium-channel blockers have caused concerns among patients taking these drugs and their physicians.
Med Lett Drugs Ther. 1997 Feb 14;39(994):13-4 | Show Full IntroductionHide Full Introduction

Drugs for Chronic Heart Failure

   
The Medical Letter on Drugs and Therapeutics • October 11, 1996;  (Issue 985)
Cardiologist now emphasize the importance of neurohormonal as well as hemodynamic factors in the pathophysiology of chronic heart failure (JN Cohn, N Engl J Med, 335:490, August 15, 1996). Drugs that act on...
Cardiologist now emphasize the importance of neurohormonal as well as hemodynamic factors in the pathophysiology of chronic heart failure (JN Cohn, N Engl J Med, 335:490, August 15, 1996). Drugs that act on different mechanisms are commonly used together.
Med Lett Drugs Ther. 1996 Oct 11;38(985):92-4 | Show Full IntroductionHide Full Introduction

Nisoldipine-A New Calcium-Channel Blocker for Hypertension

   
The Medical Letter on Drugs and Therapeutics • February 16, 1996;  (Issue 968)
Nisoldipine (Sular -Zeneca), a dihydropyridine calcium-channel blocker structurally similar to nifedipine, has been approved for marketing by the US Food and Drug Administration. It is available in an oral...
Nisoldipine (Sular -Zeneca), a dihydropyridine calcium-channel blocker structurally similar to nifedipine, has been approved for marketing by the US Food and Drug Administration. It is available in an oral extended-release formulation for treatment of hypertension.
Med Lett Drugs Ther. 1996 Feb 16;38(968):13-4 | Show Full IntroductionHide Full Introduction

Drugs for Stable Angina Pectoris

   
The Medical Letter on Drugs and Therapeutics • December 9, 1994;  (Issue 937)
Many nitrates, beta-blockers, and calcium-channel blockers have now been approved by the US Food and Drug Administration for treatment of stable angina pectoris. The table beginning on page 112 lists the...
Many nitrates, beta-blockers, and calcium-channel blockers have now been approved by the US Food and Drug Administration for treatment of stable angina pectoris. The table beginning on page 112 lists the individual drugs, their dosage, and their cost.
Med Lett Drugs Ther. 1994 Dec 9;36(937):111-4 | Show Full IntroductionHide Full Introduction

Amlodipine - A New Calcium-Channel Blocker

   
The Medical Letter on Drugs and Therapeutics • October 30, 1992;  (Issue 882)
Amlodipine (am loe' di peen) besylate (Norvasc - Pfizer), a dihydropyridine calcium-channel blocker, has been approved by the US Food and Drug Administration for once-daily oral treatment of hypertension,...
Amlodipine (am loe' di peen) besylate (Norvasc - Pfizer), a dihydropyridine calcium-channel blocker, has been approved by the US Food and Drug Administration for once-daily oral treatment of hypertension, chronic stable angina, and vasospastic (Prinzmetal's) angina.
Med Lett Drugs Ther. 1992 Oct 30;34(882):99-100 | Show Full IntroductionHide Full Introduction